Celldex Therapeutics Director Harry Penner Jr. Granted 26,000 Stock Options

This SEC Form 4 filing reports that Harry H. Penner Jr., a director of Celldex Therapeutics, Inc. (CLDX), was granted 26,000 non-qualified stock options on June 25, 2026. The options have an exercise price of $34.09 per share and vest on June 25, 2027, with an expiration date of June 25, 2036. The options were granted under the company's 2021 Omnibus Equity Incentive Plan. Following this transaction, Penner holds 26,000 options in total. The filing was signed by Sam Martin as attorney-in-fact for Harry H. Penner Jr. on June 29, 2026. This represents a standard equity compensation award to a board member as part of director compensation.